MA31017B1 - Derives d'azacycloalkane utilises comme inhibiteurs de la coenzyme a delta - 9 desaturase stearoyle. - Google Patents

Derives d'azacycloalkane utilises comme inhibiteurs de la coenzyme a delta - 9 desaturase stearoyle.

Info

Publication number
MA31017B1
MA31017B1 MA32023A MA32023A MA31017B1 MA 31017 B1 MA31017 B1 MA 31017B1 MA 32023 A MA32023 A MA 32023A MA 32023 A MA32023 A MA 32023A MA 31017 B1 MA31017 B1 MA 31017B1
Authority
MA
Morocco
Prior art keywords
delta
stearoyl
coenzyme
inhibitors
desaturase
Prior art date
Application number
MA32023A
Other languages
English (en)
Inventor
Nicolas Lachance
Chun Sing Li
Jean-Philippe Leclerc
Yeeman K Ramtohul
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of MA31017B1 publication Critical patent/MA31017B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'INVENTION PORTE SUR DES DÉRIVÉS D'AZACYCLOALKANE DE LA FORMULE STRUCTURELLE I QUI SONT DES INHIBITEURS SÉLECTIFS DE LA COENZYME A DELTA-9 DÉSATURASE- STEAROYLE (SCD1) PAR RAPPORT AUX AUTRES COENZYMES A DÉSATURASES-STEAROYLES CONNUES. LES COMPOSÉS DE L'INVENTION SONT UTILISÉS POUR PRÉVENIR ET TRAITER LES ÉTATS LIÉS À UNE SYNTHÈSE ET UN MÉTABOLISME ANORMAUX DES LIPIDES, Y COMPRIS LA MALADIE CARDIOVASCULAIRE, PAR EXEMPLE L'ATHÉROSCLÉROSE, L'OBÉSITÉ, LE DIABÈTE, LA MALADIE NEUROLOGIQUE, LE SYNDROME MÉTABOLIQUE, LA RÉSISTANCE À L'INSULINE ET LA STÉATOSE HÉPATIQUE.
MA32023A 2006-12-01 2009-06-22 Derives d'azacycloalkane utilises comme inhibiteurs de la coenzyme a delta - 9 desaturase stearoyle. MA31017B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87221606P 2006-12-01 2006-12-01
US89890007P 2007-02-01 2007-02-01

Publications (1)

Publication Number Publication Date
MA31017B1 true MA31017B1 (fr) 2009-12-01

Family

ID=39467388

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32023A MA31017B1 (fr) 2006-12-01 2009-06-22 Derives d'azacycloalkane utilises comme inhibiteurs de la coenzyme a delta - 9 desaturase stearoyle.

Country Status (24)

Country Link
US (1) US8063224B2 (fr)
EP (1) EP2099793B1 (fr)
JP (1) JP5050061B2 (fr)
KR (1) KR20090086623A (fr)
AR (1) AR064026A1 (fr)
AT (1) ATE543816T1 (fr)
AU (1) AU2007327276B2 (fr)
BR (1) BRPI0719702A2 (fr)
CA (1) CA2670703C (fr)
CL (1) CL2007003440A1 (fr)
CO (1) CO6190521A2 (fr)
CR (1) CR10858A (fr)
EA (1) EA200970524A1 (fr)
EC (1) ECSP099375A (fr)
GT (1) GT200900144A (fr)
IL (1) IL198824A0 (fr)
MA (1) MA31017B1 (fr)
MX (1) MX2009005713A (fr)
NO (1) NO20092469L (fr)
PE (1) PE20081199A1 (fr)
SV (1) SV2009003275A (fr)
TN (1) TN2009000212A1 (fr)
TW (1) TW200826936A (fr)
WO (1) WO2008064474A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1315831B8 (fr) * 2000-02-24 2010-09-01 Xenon Pharmaceuticals Inc. Methodes et compositions utilisant la stearoyl-coa desaturase pour identifier des agents therapeutiques reduisant les triglycerides
EP2027121A1 (fr) * 2006-05-22 2009-02-25 Merck Frosst Canada Ltd. Dérivés d'amines cycliques en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9-désaturase
WO2007143823A1 (fr) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Dérivés d'azétidine comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
US7754745B2 (en) 2006-06-13 2010-07-13 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2007283401A1 (en) * 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
AR064965A1 (es) * 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
AU2008241313A1 (en) * 2007-04-20 2008-10-30 Merck Frosst Canada Ltd. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2008253512A1 (en) * 2007-05-23 2008-11-27 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
US7842696B2 (en) 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
AR067557A1 (es) * 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
WO2009012573A1 (fr) * 2007-07-20 2009-01-29 Merck Frosst Canada Ltd. Composés hétéroaromatiques bicycliques en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
EP2334666A1 (fr) * 2008-09-08 2011-06-22 Merck Canada Inc. Composes heteroaromatiques utilises en tant qu'inhibiteurs de la stearoyle-coenzyme a delta-9 desaturase
WO2010094120A1 (fr) * 2009-02-17 2010-08-26 Merck Frosst Canada Ltd. Nouveaux composés spiro utiles comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
CA2750635A1 (fr) * 2009-02-23 2010-08-26 Merck Canada Inc. Derives heterocycliques comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
US20120010186A1 (en) * 2009-03-23 2012-01-12 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8383643B2 (en) 2009-07-28 2013-02-26 Merck Canada Inc. Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
BR112012027762B1 (pt) 2010-04-28 2018-06-05 Bayer Intellectual Property Gmbh Derivados de cetoheteroarilpiperidina e - piperazina como fungicidas
PL2668182T3 (pl) * 2011-01-28 2018-11-30 Immunic Ag Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
WO2013062882A1 (fr) * 2011-10-26 2013-05-02 Merck Canada Inc. Inhibiteurs de la scd pour le traitement du vhc
WO2013134546A1 (fr) 2012-03-07 2013-09-12 Mayo Foundation For Medical Education And Research Procédés et matériaux pour traiter le cancer
MX2014014174A (es) 2012-05-22 2015-07-06 Hoffmann La Roche Inhibidores selectivos de celulas no diferenciadas.
WO2016022955A1 (fr) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Composés et méthodes de traitement du cancer
EP3529245A4 (fr) * 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. Composés et utilisations de ces derniers
MA47212A (fr) * 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
WO2019084157A1 (fr) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Composés et utilisations de ces composés
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
MA54829A (fr) 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1595923A1 (de) * 1965-02-20 1969-11-27 Merck Ag E 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
KR20060037410A (ko) 2003-07-30 2006-05-03 제논 파마슈티칼스 인크. 피리다진 유도체 및 그의 치료제로서의 용도
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
EP1799667B1 (fr) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
CN101083986A (zh) 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
EP2316458A1 (fr) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Derives de pyridazine destines a l'inhibition du desaturase-coa-stearoyl de l'humain
EP2289510A1 (fr) * 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques pour le traitement des maladies induites par des enzymes stearoyl-coa desaturase
EP1804799B1 (fr) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'agents thérapeutiques
CA2580856A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US7767677B2 (en) * 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion
WO2006125181A2 (fr) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Derives piperidiniques: utilisation comme agents therapeutiques
EP1902051A1 (fr) 2005-06-09 2008-03-26 Merck Frosst Canada Ltd. Derives d'azacyclohexane comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
WO2007009236A1 (fr) 2005-07-20 2007-01-25 Merck Frosst Canada Ltd. Composes heteroaromatiques servant d'inhibiteurs d'une coenzyme stearoyle a delta-9 desaturase
JP2009510132A (ja) 2005-10-05 2009-03-12 メルク フロスト カナダ リミテツド ロイコトリエン生合成の阻害剤としての置換キノリン
AU2006315025A1 (en) 2005-11-15 2007-05-24 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2007071023A1 (fr) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Composés hétéroaromatiques en tant qu'inhibiteurs de stéaroyl-coenzyme a delta-9 désaturase
EP2027121A1 (fr) 2006-05-22 2009-02-25 Merck Frosst Canada Ltd. Dérivés d'amines cycliques en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9-désaturase
WO2007143823A1 (fr) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Dérivés d'azétidine comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
US7754745B2 (en) 2006-06-13 2010-07-13 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2007283401A1 (en) 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
US20100004245A1 (en) 2006-10-20 2010-01-07 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (es) * 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa

Also Published As

Publication number Publication date
EP2099793A4 (fr) 2010-12-29
TN2009000212A1 (en) 2010-10-18
GT200900144A (es) 2011-06-23
EP2099793B1 (fr) 2012-02-01
MX2009005713A (es) 2009-06-08
AR064026A1 (es) 2009-03-04
ECSP099375A (es) 2009-07-31
CR10858A (es) 2009-06-25
KR20090086623A (ko) 2009-08-13
ATE543816T1 (de) 2012-02-15
AU2007327276A1 (en) 2008-06-05
AU2007327276B2 (en) 2011-06-09
PE20081199A1 (es) 2008-10-19
JP5050061B2 (ja) 2012-10-17
CA2670703C (fr) 2012-05-15
CA2670703A1 (fr) 2008-06-05
IL198824A0 (en) 2010-02-17
JP2010510993A (ja) 2010-04-08
EP2099793A1 (fr) 2009-09-16
NO20092469L (no) 2009-08-27
BRPI0719702A2 (pt) 2013-12-17
SV2009003275A (es) 2009-11-18
US20080132542A1 (en) 2008-06-05
TW200826936A (en) 2008-07-01
CL2007003440A1 (es) 2008-04-04
CO6190521A2 (es) 2010-08-19
US8063224B2 (en) 2011-11-22
EA200970524A1 (ru) 2009-12-30
WO2008064474A1 (fr) 2008-06-05

Similar Documents

Publication Publication Date Title
TN2009000212A1 (en) Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
MA27579A1 (fr) Derives de triazole comme inhibiteurs de la 11-beta-hydroxysteroide-deshydrogenase 1
MA27725A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
MA30686B1 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase.
PT1960352E (pt) Derivados de 2-adamantilureia como inibidores seletivos de 11â-hsd1
MA30476B1 (fr) Derives de type cyclohexylpyrazole-lactame comme inhibiteurs de la 11-beta-hydroxysteroïde deshydrogenase de type 1
TNSN06359A1 (fr) Aryl-ou heteroaryl-amides substitues en position ortho
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA28130A1 (fr) Derives aryle et heteroaryle condenses utilises comme modulateurs du metabolisme et prophylaxie et traitement des troubles metaboliques.
WO2003104207A3 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utilisables pour le traitement du diabete, de l'obesite et de la dyslipidemie
IL213425A0 (en) Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
MA31319B1 (fr) Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
EA201300759A1 (ru) Новые производные nip тиазола в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы-1
CY1113645T1 (el) Παραγωγα 7-αζαϊνδολης ως επιλεκτικοι αναστολεις 11-βητα-υδροξυστεροειδους δεϋδρογενασης τυπου 1
MA30228B1 (fr) Pipéridinoylpyrrolidines agonistes du récepteur de mélanocortine de type 4
MA29807B1 (fr) Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques.
MA31841B1 (fr) Modulateurs du gpr40 à biphényle substitué
MA30289B1 (fr) Dérivés d'amines
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
ATE556050T1 (de) Inhibitoren des 11-beta-hydroxysteroid- dehydrogenase-1-enzyms
MA29805B1 (fr) Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques
MA29746B1 (fr) Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l'hepatite c
MA31084B1 (fr) Derives de piperidine agonistes de gpcr